| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.63B | +3.5% |
| Gross profit | ¥0.21B | — |
| Operating income | ¥0.11B | — |
| Net income | ¥0.09B | +22.1% |
| Gross margin | 33.8% | Net margin 14.4% |
| Revenue Q/Q | +37.2% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.42B | 66.2% |
| R&D | ¥0.01B | 1.1% |
| SG&A | ¥0.08B | 13.1% |
| Tax & other | ¥0.02B | 2.8% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
宜通世纪 ・ ST任子行 ・ 天山生物 ・ 戴维医疗 ・ 掌趣科技 ・ 珈伟新能 ・ 博晖创新 ・ 麦捷科技 ・ 海达股份 ・ 同大股份 ・ 硕贝德 ・ 华灿光电
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies